Navigation Links
Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial
Date:5/4/2009

rican Cystic Fibrosis conference in Minneapolis in October.

Bronchitol has received Orphan Drug Designation and development fast track status from the U.S. Food and Drug Administration and Orphan Drug Designation from the European Medicines Agency.

Bronchitol is designed to hydrate the airway surface of the lungs, and promote normal lung mucus clearance. No new products have been approved anywhere in the world for cystic fibrosis for more than 10 years.

Dr Alan Robertson said: "We recognise that many people have been involved in the development of Bronchitol and their assistance has been invaluable. The trial was complex and challenging and this landmark result is a tribute to their efforts."

Dr Alan Robertson will host a teleconference to discuss the results on Tuesday 5th May at 8.00am (Sydney), (Monday 4th May at 6.00pm U.S. East Coast, 3.00pm U.S. West Coast).

    Telephone access (toll free) details are below:

    -- Australia: 1800 131 617
    -- USA/Canada:  866 746 2596
    -- UK: 0800 376 8339
    -- NZ: 0800 446 958
    -- Switzerland: 0800 001 230
    Online (global access):
http://services.choruscall.com/links/pharmaxis090505.html

About Pharmaxis

Pharmaxis (ACN 082 811 630) is a specialist pharmaceutical company involved in the research, development and commercialization of therapeutic products for chronic respiratory and immune disorders. Its development pipeline of products includes Aridol for the diagnosis of asthma, Bronchitol for cystic fibrosis, bronchiectasis and chronic obstructive pulmonary disease (COPD), PXS25 for the treatment of lung fibrosis and PXS4159 for asthma. Founded in 1998, Pharmaxis is listed on the Australian Securities Exchange (symbol PXS), and on NASDAQ Global Market (symbol PXSL). The company is headquartered in Sydn
'/>"/>

SOURCE Pharmaxis Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmaxis Announces Milestone in Phase III Trial for Cystic Fibrosis
2. Pharmaxis Announces New Drug Application Submission for Aridol(TM)
3. ASX/NASDAQ Media Release: Pharmaxis Files First Marketing Application for Bronchitol in Australia
4. Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial
5. Pharmaxis Establishes Named Patient Program for Bronchitol
6. Pharmaxis Long-Term Safety Study of Bronchitol Completes
7. Sirion Therapeutics Announces Clinical Data Presentations at the 2009 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
8. Optherion Announces Issuance of Canadian Patents Covering Age-Related Macular Degeneration Diagnostics and Treatments
9. Video: ev3 Inc. Announces First Patient Enrollments in DEFINITIVE LE Post-Market Study
10. Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients
11. Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... Solutions, Inc. (NASDAQ: BLFS ), a leading developer, manufacturer ... and cryopreservation freeze media and precision thermal ... "Company"), announced that the Company is scheduled to present at ... is scheduled to present at the Conference at 1:30 p.m. ... Hotel in New York City and ...
(Date:5/22/2015)... FORT WORTH, Texas , May 22, 2015 ... at $58.4 million in 2014 and is estimated to reach ... 2014 to 2019. Browse through the TOC of ... trends and segments, with the help of various tables and ... buyers will receive 10% customization on this report.   ...
(Date:5/22/2015)...  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" ... the results of the Company,s 72-patient, placebo-controlled Phase ... for the treatment of dry eye patients using ... model.  The exploratory study was completed in late ... by the Company in a press release, identify ...
Breaking Medicine Technology:BioLife Solutions To Present At The 2015 Marcum MicroCap Conference In New York City 2North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 2North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 2Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 4
... 2 /PRNewswire-Asia-FirstCall/ -- Biostar Pharmaceuticals, Inc. (OTC Bulletin ... developer, manufacturer and supplier of pharmaceutical products and ... conditions, today announced it has received a patent ... Aoxing Ganbao product. The patent number is 551073. ...
... NEW YORK, Oct. 1 Intercept Pharmaceuticals, Inc., has ... INT-747 has met the primary endpoint of improved insulin ... trial in type 2 diabetic patients with nonalcoholic fatty ... clamp procedure, the study demonstrated that a single oral ...
Cached Medicine Technology:Biostar Pharmaceuticals, Inc. Receives Patent for Aoxing Ganbao 2Biostar Pharmaceuticals, Inc. Receives Patent for Aoxing Ganbao 3Intercept Pharmaceuticals' FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease 2
(Date:5/22/2015)... Pa (PRWEB) May 22, 2015 ... (AHN) today announced a new partnership to develop ... for the region. The initiative includes a new exhibit ... live demonstration theater, and a new traveling science ... the fall of 2015. , Designed to explore ...
(Date:5/22/2015)... VIEW, California (PRWEB) May 22, 2015 Coco ... has set a RecordSetter.com World Record at the 104th running ... Libre coconut water ice luge served 315 people in one ... Bay to Breakers race is so true to the heart ... we felt bringing an ice luge to the finish line ...
(Date:5/22/2015)... NY (PRWEB) May 22, 2015 Medivo, Inc., ... “Positivity Rates and Genotype Results in ‘Baby Boomers’ Screened ... from a Nationwide Lab Test Database” at Digestive Disease Week, ... Medivo’s Clinical Affairs and Analytics team members Carol Smyth, MB; ... and Andrea Parker, MSI, along with Nancy Reau, MD from ...
(Date:5/22/2015)... York, NY (PRWEB) May 22, 2015 Ticket ... Lightning vs. New York Rangers NHL Eastern Conference Finals Tickets ... is together unless specified otherwise in the ticket listing. ... York Rangers are at the top of the Eastern Conference. ... has had its share of ups and downs over the ...
(Date:5/22/2015)... May 22, 2015 A new program ... experts in the field of Physical Therapy. , ... takes the mystery out of physical therapy and discusses ... of motion for a variety of ailments and injuries. ... a personalized exercise plan that enhances daily activities such ...
Breaking Medicine News(10 mins):Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 3Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 4Health News:Coco Libre Ice Luge Sets New World Record at Bay to Breakers 2Health News:Medivo Study Finds HCV Positivity Rates are 250% Higher Among Baby Boomers 2Health News:Cheap Lightning vs Rangers NHL Eastern Conference Finals Tickets: Ticket Down Slashes Ticket Prices on New York Rangers vs Tampa Bay Lightning Eastern Conference Playoffs 2Health News:Cheap Lightning vs Rangers NHL Eastern Conference Finals Tickets: Ticket Down Slashes Ticket Prices on New York Rangers vs Tampa Bay Lightning Eastern Conference Playoffs 3
... SEATTLE The worst global economic crisis in decades ... record amounts of money to health assistance for developing ... for Health Metrics and Evaluation (IHME) at the University ... health has grown 375% from $5.66 billion in 1990 ...
... obstructive sleep apnea (OSA), a sleep disorder associated with ... coronary arteries, according to a study presented today at ... America (RSNA). "Our study reveals that individuals with ... form of atherosclerosis that puts them at risk for ...
... say they have found an effective two-part treatment for microtears ... a steroid along with "dry-needling," in which repeated needle punctures ... the study were presented today at the annual meeting of ... the patient,s own blood where it is needed at the ...
... CHICAGO Using functional magnetic resonance imaging (fMRI), researchers ... a pain stimulus with and without acupuncture to determine ... of the study, which the researchers say suggest the ... meeting of the Radiological Society of North America (RSNA). ...
... CA, November 30, 2010 In the wake of multiple ... warning to four companies to remove their products from the ... of Preventive Medicine delineates the scope of the public health ... it. "Although several manufacturers of caffeinated beer have withdrawn ...
... (November 29, 2010) Whitehead Institute researchers have shown ... (miR-125b) can independently cause leukemia and accelerate the disease,s ... edition of the Proceedings of the National Academy of ... but in humans and mice, can upregulation of a ...
Cached Medicine News:Health News:Despite economic slump, donors give generously to global health, though at a slower rate 2Health News:Despite economic slump, donors give generously to global health, though at a slower rate 3Health News:People with sleep apnea at higher risk for aggressive heart disease 2Health News:Researchers use patient's own blood to treat hamstring injury 2Health News:Acupuncture changes brain's perception and processing of pain 2Health News:Caffeinated alcoholic beverages -- a growing public health problem 2Health News:Tiny RNA shown to cause multiple types of leukemia 2Health News:Tiny RNA shown to cause multiple types of leukemia 3
The Astigmatome makes precise and accurate cuts for astigmatism correction simply and safely. The procedure can be done in the office under topical anesthesia. Complete Set Includes Vacuum Speculum, ...
... of temporary sensing and pacing leads. Our ... temporary pacing leads and improved upon the ... and less traumatic to heart tissue. , ... to provide consistent temporary sensing and pacing ...
... indication for this technique is acquired ... Indications for tricuspid repair are based ... as diagnosed by angiography and dye ... In patients with an irreversible tricuspid ...
... Pro Medical Billing proudly offers distinct ... your area of expertise. ... diagnosis codes and medical records templates ... practice, ob/gyn, sports medicine, ophthalmology, allergy, ...
Medicine Products: